Table 3. Screening tests and results among women attending selected basic health units, 2019 campaign (Manaus, Brazil).
| Region/ Basic Health Unit | Number of cytology tests 2019 campaigna | Total HSIL+ results | ||
|---|---|---|---|---|
| N | % | |||
| South zone | UBS 1 | 65 | 5 | 7.7 |
| UBS 2 | 86 | 5 | 5.8 | |
| UBS 3 | 52 | 8 | 15.4 | |
| UBS 4 | 49 | 5 | 10.2 | |
| North zone | UBS 1 | 151 | 7 | 4.6 |
| UBS 2 | 120 | 5 | 4.2 | |
| UBS 3 | 98 | 3 | 3.1 | |
| UBS 4 | 211 | 3 | 1.4 | |
| East zone | UBS 1 | 185 | 11 | 5.9 |
| UBS 2 | 109 | 9 | 8.3 | |
| UBS 3 | 98 | 2 | 2.0 | |
| UBS 4 | 61 | 7 | 11.5 | |
| Total | 1,285 | 70 | 5.4 | |
UBS: Unidade Básica de Saúde; HSIL+: High-grade intraepithelial lesion or worse (includes atypical squamous cells cannot rule out high grade (ASC-H), atypical glandular cells of undetermined significance (AGUS) and cancer).
aOne-month screening campaign, Pink October, among women age 25–64.